Stifel analyst Alex Thompson raised the firm’s price target on Celldex (CLDX) to $68 from $58 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex Therapeutics: Early EMBARQ Enrollment and 2026 Data Catalysts Underscore Attractive Risk‑Reward and Support Buy Rating
- Maintaining Buy on Barzolvolimab: Accelerated Clinical Execution, Best-in-Class Potential, and 2026 Catalyst-Driven Upside
- Celldex reports Q4 EPS ($1.22), consensus ($1.00)
- Celldex completes enrollment in Phase 3 studies of barzolvolimab
- Celldex’s EvolvE Study Completion Sets Up Key Catalyst in Eosinophilic Esophagitis